Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale

BACKGROUND: Diuretic Resistance in Acute Heart Failure (DR-AHF) was designed to demonstrate the effectiveness of the early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in patients with AHF with renal dysfunction and to provide clinical evidence of loop diuretic resistance. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Minh, Nhat Giang, Hoang, Hai Nguyen, Maeda, Daichi, Matsue, Yuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829876/
https://www.ncbi.nlm.nih.gov/pubmed/35155599
http://dx.doi.org/10.3389/fcvm.2021.783181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829876/
https://www.ncbi.nlm.nih.gov/pubmed/35155599
http://dx.doi.org/10.3389/fcvm.2021.783181

Ejemplares similares